6 assets in Primary Cutaneous Anaplastic Large Cell Lymphoma

Therapeutic assets addressing Primary Cutaneous Anaplastic Large Cell Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Brentuximab Vedotin Primary Cutaneous Anaplastic Large Cell Lymphoma	John Reneau	P3	BB (67)
Anti-Cd30 Bispecific Antibody-Armed Anti-Cd3-Activated Autologous T-Cells Primary Cutaneous Anaplastic Large Cell Lymphoma	Medical College of Wisconsin	P1	CC (43)
Atlcar.Cd30.Ccr4 Cells Primary Cutaneous Anaplastic Large Cell Lymphoma	UNC Lineberger Comprehensive Cancer Center	P1	CC (43)
Bendamustine Primary Cutaneous Anaplastic Large Cell Lymphoma	UNC Lineberger Comprehensive Cancer Center	P1	CC (43)
Fludarabine Primary Cutaneous Anaplastic Large Cell Lymphoma	UNC Lineberger Comprehensive Cancer Center	P1	CC (43)
Gm-Csf Primary Cutaneous Anaplastic Large Cell Lymphoma	Medical College of Wisconsin	P1	CC (43)